Shanghai Friendess Electronic Technology Corp Ltd

CN

Information Technology

308.5 ₽

Current price

Buy
308.5 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    117 / 690

  • Position in country

    1273 / 7387

  • Return on Assets, %

    15.6

    2.2

  • Net income margin, %

    49.5

    3.6

  • EBITDA margin, %

    47.9

    8.2

  • Debt to Equity, %

    0.3

    13.9

  • Intangible assets and goodwill, %

    2.4

    2.4

  • Revenue CAGR 3Y, %

    35

    6.4

  • Total Equity change 1Y, %

    12.9

    -0.1

  • Revenue Y, % chg

    48.6

    0

  • P/E

    59.7

    25.7

  • P/BV

    8.7

    1.8

  • P/S

    31

    2.7

  • EV/S

    27.9

    2.4

  • EV/EBITDA

    53.9

    10.4

  • Average Analyst recommendation

    Buy

    Buy

  • Average upside forecasts, %

    6

    37.6

  • Forward P/E

    39.2

    17.8

  • Forward Dividend Yield, %

    0.1

    0.1

  • Expected dividend per share

    0.4

    0

  • Payout Ratio, %

    50.3

    27.1

Get an analytical review of this company

Competitors

Ranks

  • Shanghai Friendess Electronic Technology Corp Ltd

    00%

  • Universal Scientific Industrial Shanghai Co Ltd

    00%

  • SUPCON Technology Co Ltd

    00%

  • Zhejiang Dahua Technology Co Ltd

    00%

  • Huagong Tech Co Ltd

    00%

  • Hangzhou EZVIZ Network Co Ltd

    00%

  • Hangzhou Hikvision Digital Technology Co Ltd

    00%

  • TCL Technology Group Corp

    00%

  • China Railway Signal & Communication Corp Ltd

    00%

  • Wuhan Guide Infrared Co Ltd

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    China

  • Sector

    Information Technology

  • Industry group

    Technology Hardware & Equipment

  • Industry

    Electronic Equipment, Instruments & Components

  • Sub-sector

    Information Technology

  • Capitalization (millions of $)

    6033

  • Ticker

    688188.SS

  • ISIN

    CNE100003LY6

  • IPO date

    2019-08-08

  • Availability on Russian exchanges

    No

  • Reporting for

    2024-03-19

  • Date fact. publication of reports

    2023-12-31

Company Description

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: